StreetAlpha.app
Home › Stocks › PBYI

Puma Biotechnology, Inc. (PBYI)

$7.05
▼ −0.98%
LAST CLOSE · NOV 20

Puma Biotechnology develops and sells cancer treatments, including the breast cancer drug NERLYNX. It last closed at $7.05 on Nov 20, down 0.98% on the day. The next earnings report for PBYI is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, PBYI reported EPS of $0.11 on revenue of $55.1M, with revenue up 1.1% from a year ago. Over its last 8 reports the stock moved an average of 14.1% the session after earnings. Over the last 12 months PBYI insiders bought $0 of stock on the open market and sold $2.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is PBYI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PBYI.

Key Stats

Last 12 months
Results
Revenue
$231.8M
+9.4% vs a year ago
Net income
$23.8M
−35.6% vs a year ago
EPS (diluted)
$0.46
−38.7% vs a year ago
Free cash flow
$46.0M
19.8% margin
Valuation
Market cap
$364.5M
51.7M shares
P/E
15.3
Price over 12 month EPS
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.5M
At Sep 30
Debt
$0
At Jun 30
Shareholder equity
$146.6M
Shares outstanding
51.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $253.2M$253.2MFY2021FY2022: $228.0M$228.0MFY2022FY2023: $235.6M$235.6MFY2023FY2024: $230.5M$230.5MFY2024FY2025: $228.4M$228.4MFY2025

From PBYI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
$0.11
Quarter ended Sep 2026
Year ago EPS
$0.17
−35.3% on a GAAP basis
Revenue
$55.1M
+1.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.40Dec '24Mar 2025: $0.06Mar '25Jun 2025: $0.12Jun '25Sep 2025: $0.17Sep '25Dec 2025: $0.26Dec '25Mar 2026: -$0.07Mar '26Jun 2026: $0.16Jun '26Sep 2026: $0.11Sep '26Latest $0.11
Revenue by quarter
Dec 2024: $59.1MDec '24Mar 2025: $46.0MMar '25Jun 2025: $52.4MJun '25Sep 2025: $54.5MSep '25Dec 2025: $75.5MDec '25Mar 2026: $44.8MMar '26Jun 2026: $56.5MJun '26Sep 2026: $55.1MSep '26Latest $55.1M
How PBYI moved after its last 8 reports
Average move the session after a report ±14.1%
Nov 5, 2026After the close−15.6%
Aug 6, 2026After the close+9.7%
May 7, 2026After the close+3.2%
Feb 26, 2026After the close−25.0%
Nov 6, 2025After the close+22.2%
Aug 7, 2025After the close+12.2%
May 8, 2025After the close−5.2%
Feb 27, 2025After the close+19.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PBYIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PBYI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PBYI

Technical Analysis

PBYI · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 27% below its 20 day and 35% below its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the swing low (Jun 16) at $6.96, and the nearest resistance the Pivot at $7.06.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 6.8%/day
Key levels
$11.5052 week high+63.1%
$9.5450 day average+35.3%
$9.08100 day average+28.8%
$8.9420 day average+26.8%
$8.04200 day average+14.0%
$7.45Swing high (May 27)+5.7%
$7.21Pivot R1+2.3%
$7.06Pivot+0.1%
$7.05Last close
$6.96Swing low (Jun 16)−1.3%
$6.90Pivot S1−2.1%
$4.7952 week low−32.1%
Indicators
RSI (14)24.46Oversold below 30Oversold
MACD-0.81Below its signal lineBearish
Stochastic5.4Near the bottom of its rangeOversold
ADX (14)37.9Trending down
Williams %R-96.5Oversold below −80, overbought above −20Oversold
CCI (20)-92.2Oversold below −100, overbought above 100Neutral
Rate of change−14.6%Change over 10 sessionsBearish
ATR (14)$0.48Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PBYI

What happened before

See how PBYI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PBYI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PBYI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PBYIHow many large options trades hit PBYI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PBYI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲86 buying vs 65 selling
  • ▲Held by funds +8.6 pts
  • ▼Funds holding -3
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158161−1.9%
In funds' top 10110.0%
Held by funds83.4%74.8%+8.6 pts
New / increased22 / 6421 / 59+7.5%
Reduced / sold out40 / 2551 / 16−3.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PBYI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PBYI Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.1M14 sales · 10 insiders
94% of the selling was under pre-arranged trading plans.
2026-01 sold $322K2026-06 sold $573K2026-07 sold $512K2026-09 sold $612K2026-11 sold $121KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Michael Patrick MillerDirectorSale15,000$8.10$121K
Sep 14Alessandra CesanoDirectorSale plan62,150$9.12$567K
Sep 14Troy Edward WilsonDirectorSale plan5,000$9.10$46K
Jul 6Maximo F NouguesCFOSale plan9,386$8.26$78K
Jul 6Douglas M HuntSee RemarksSale plan8,460$8.26$70K
Jul 6Alan H AuerbachPresident and CEOSale plan44,058$8.26$364K
Every insider buy and sale for PBYI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PBYI insider trades →

From SEC Form 4 filings by PBYI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PBYI is in one of them and how their past PBYI trades turned out.

PBYI in the AI portfolios
Loading…

PBYI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PBYI in an article yet. Here's the latest on the wider market.

PBYI in the news

PBYI Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 27
Who traded PBYI · since 2014
Latest 5 filings of 7
$1K – $15KTraded May 15, 2019Filed Apr 27, 2020
$1K – $15KTraded Jan 23, 2019Filed Apr 27, 2020
$1K – $15KTraded Sep 26, 2014Filed Oct 13, 2014
$1K – $15KTraded Sep 10, 2014Filed Oct 13, 2014
$1K – $15KTraded Jul 30, 2014Filed Aug 14, 2014
PersonTypeAmountTradedFiledDelay
Donna ShalalaD · FLSell$1K – $15KMay 15, 2019Apr 27, 2020348 d
Donna ShalalaD · FLBuy$1K – $15KJan 23, 2019Apr 27, 2020460 d
Nick J. RahallD · WVSell$1K – $15KSep 26, 2014Oct 13, 201417 d
Nick J. RahallD · WVBuy$1K – $15KSep 10, 2014Oct 13, 201433 d
Nick J. RahallD · WVBuy$1K – $15KJul 30, 2014Aug 14, 201415 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Puma Biotechnology

Puma Biotechnology is a biopharmaceutical company based in Los Angeles, California, that develops and sells cancer treatments. Its main commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain types of HER2 positive breast cancer. In the United States the company markets NERLYNX through its own sales force, and it works with partners in other countries to sell the drug there. It is also developing alisertib, an investigational cancer drug aimed at small cell lung cancer and hormone receptor positive breast cancer.

Headquarters
Los Angeles, CA